PharmacoEconomics & Outcomes News 695, p10 - 1 Feb 2014 Disappointment at lack of reimbursement for CRC drugs The Colorectal Cancer Association of Canada (CCAC) is "very concerned" that new drugs for the treatment of metastatic colorectal cancer (mCRC) have not been recommended for public funding. Both regorafenib [Stivarga] and cetuximab [Erbitux] failed to be recommended by the pan-Canadian Oncology Drug Review (pCODR) – a decision which was a "great disappointment to patients, caregivers and the colon cancer community". President of the CCAC, Barry Stein, says that "the cost of these new products can be high, however, the benefit to society and to patients of developing these new drugs should not be such that patients lose the opportunity to benefit from them due to their cost alone". Colorectal Cancer Association of Canada. Canadians are still frustrated at lack of affordable access to new cancer medicines. Media Release : 27 Jan 2014. Available from: URL: http://www.colorectal-cancer.ca 809158710 1 PharmacoEconomics & Outcomes News 1 Feb 2014 No. 695 1173-5503/14/0695-0001/$14.95 Adis © 2014 Springer International Publishing AG. All rights reserved

Disappointment at lack of reimbursement for CRC drugs

Download PDF Report

Upload
harry-p
View
215
Download
1

Embed Size (px)

Citation preview

PharmacoEconomics & Outcomes News 695, p10 - 1 Feb 2014

Disappointment at lack ofreimbursement for CRC drugs

The Colorectal Cancer Association of Canada (CCAC)is "very concerned" that new drugs for the treatment ofmetastatic colorectal cancer (mCRC) have not beenrecommended for public funding.

Both regorafenib [Stivarga] and cetuximab [Erbitux]failed to be recommended by the pan-CanadianOncology Drug Review (pCODR) – a decision whichwas a "great disappointment to patients, caregivers andthe colon cancer community". President of the CCAC,Barry Stein, says that "the cost of these new products canbe high, however, the benefit to society and to patientsof developing these new drugs should not be such thatpatients lose the opportunity to benefit from them dueto their cost alone".Colorectal Cancer Association of Canada. Canadians are still frustrated at lack ofaffordable access to new cancer medicines. Media Release : 27 Jan 2014.Available from: URL: http://www.colorectal-cancer.ca 809158710